Simone Biles Partnered with Skincare Brand Arcutis
The athlete is helping raise awareness about treatment options for chronic inflammatory skin conditions.
Updated on Oct. 10, 2026 in Beauty
Live Poll
Do you trust medical treatment recommendations more when they are promoted by famous celebrities?
Olympic gymnast Simone Biles has partnered with Arcutis Biotherapeutics to promote the company's Zoryve medication line. The campaign aims to encourage the millions of Americans living with inflammatory skin conditions to consult healthcare providers about their symptoms.
Why it matters
More than 36 million people in the U.S. live with conditions like eczema and seborrheic dermatitis, yet over half currently do not seek professional treatment. This initiative highlights the importance of connecting with dermatologists to address skin health.
In Q2 2026, Zoryve foam generated $67.4 million in sales, while the cream formulation reached $62.4 million. The efficacy and safety profile of these products were established leading up to the FDA approval first granted in 2022.
The players
Simone Biles
An Olympic gymnast who is serving as a brand partner to raise awareness about chronic inflammatory skin conditions.
Arcutis Biotherapeutics
A pharmaceutical company that focuses on developing and marketing dermatological treatments for inflammatory conditions.
The details
Zoryve products are prescription-based treatments used for inflammatory skin conditions including eczema and seborrheic dermatitis. The brand recently launched a virtual platform to facilitate easier access to dermatological care. Biles began using the products after publicly sharing her own skin health challenges during the 2024 Paris Olympics.
Timeline
Zoryve received its initial FDA approval in 2022.
The Zoryve foam product officially launched in 2023.
Biles shared her skin symptoms during the Summer 2024 Paris Olympics.
Sales figures for Q2 2026 were reported for both foam and cream products.
Potential FDA label expansion for pediatric use is expected in 2027.
Health Landscape
The pharmaceutical sector is increasingly prioritizing patient-access platforms to bridge the gap in dermatological care. This shift follows the trend where millions of patients remain unmanaged for chronic skin issues despite the availability of newer, non-steroidal treatment options.
If you are managing persistent skin irritation, it is worth discussing your symptoms with a dermatologist to determine if prescription treatments are appropriate. Always speak with your doctor to evaluate whether new medications align with your specific medical history and current health needs.
The takeaway
Recognizing that skin conditions are common and treatable is the first step toward effective symptom management. If you suspect an inflammatory condition, track your symptoms and consult with a dermatologist to explore current, clinically-supported care options.
What happens next
Arcutis Biotherapeutics anticipates a potential FDA approval decision regarding the use of Zoryve in infants aged three to 24 months in 2027.
Further reading
For more information on the latest developments in skin health, visit our Beauty section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Do you trust medical treatment recommendations more when they are promoted by famous celebrities?
